Who
Susan Rodriguez
Director
Company insider
Files Form 4 as: Director, Veradigm; Ccso, Monopar Therapeutics; Chief Operating Officer, Avadel Pharmaceuticals; Director, Heron Therapeutics; Chief Commercial Officer, Ardelyx.
In numbers
- Trades disclosed
- 50
- Buys
- 0
- Sells
- 16
- Bought
- $0
- Sold
- $275K
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 18 May 2020
- Last trade
- 1 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 3 Jun 2026 | VeradigmIT Services & Consulting | SEC FORM 4 Code A | —42,507 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | Veradigm | SEC FORM 4 Code A | —42,507 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,728 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,728 at $0.00 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —300,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —300,000 | filing |
| 2 Jun 2025filed 3 Jun 2025 | Veradigm | SEC FORM 4 Code A | $200K46,512 at $4.30 | filing |
| 13 May 2025filed 13 May 2025 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,900 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code A | —17,950 at $0.00 | filing |
| 30 Jan 2025filed 3 Feb 2025 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $62K35,900 at $1.73 | filing |
| 30 Jan 2025filed 3 Feb 2025 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code A | —17,950 at $0.00 | filing |
| 31 May 2024filed 20 Jun 2024 | Veradigm | SEC FORM 4 Code A | —42,106 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $52K6,703 at $7.81 | filing |
| 20 Feb 2024filed 22 Feb 2024 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $61K6,928 at $8.75 | filing |
| 19 Jan 2024filed 19 Jan 2024 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —83,685 at $0.00 | filing |
| 19 Jan 2024filed 19 Jan 2024 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code A | —13,948 at $0.00 | filing |
| 16 Jan 2024filed 18 Jan 2024 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —145,000 at $0.00 | filing |
| 16 Jan 2024filed 18 Jan 2024 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —112,750 at $0.00 | filing |
| 20 Nov 2023filed 22 Nov 2023 | ARDX ArdelyxBiotechnology | SEC FORM 4 Sold | $21K4,714 at $4.36 | filing |
News
November 16, 2026 Deadline: Join Class Action Lawsuit Against Ardelyx, ...ARDX · pr-inside.com · 20 Oct 2026ARDX Shareholder Alert: Ardelyx, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallStARDX · prnewswire.com · 15 Oct 2026ARDX Stockholders Have Rights - If You Lost Money Investing in Ardelyx, Inc. Contact Robbins LLP for Information About Recovering Your LossesARDX · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name Susan Rodriguez; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.